HIV Drug Market Share & Industry Growth, 2022

  • Published on
    21-Apr-2017

  • View
    40

  • Download
    4

Transcript

PowerPoint Presentation

HIV Drug MarketOpportunities and Forecasts, 2014 - 2022 Pages: 163Published: 2017

HIV DRUG MARKETMARKETNorth America and Europe are expected to dominate the global HIV drug market during the forecast period, while emerging countries in Asia-Pacific and Latin America are expected to offer significant growth opportunities.Hemali Narkhede

HIV Drug Marketreport, published by Allied Market Research, forecasts that the global market is expected to garner $26,458 million by 2022, registering a CAGR of 3.7% during the period 2016 - 2022.

The multi-class combination drug segment held over one-third share of the total market in 2015.

Multi-class combination drugs segment had accounted for more than one-third revenue of the overall HIV drug market in 2015, owing to increase in adoption of combination drugs from this medication class due to their better results in the control of HIV & related coinfections and their ease in consumption & adherence.

Read more at : https://www.alliedmarketresearch.com/hiv-drugs-market

HIV DRUG MARKET MARKET OVERVIEW

HIV DRUG MARKETMARKET KEY BENEFITSThe study provides an in-depth analysis of the HIV drugs market, with current trends and future estimations to elucidate the imminent investment pockets.

It presents a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.

Extensive analysis of the HIV drug market, by medication class, assists in the effective treatment of HIV/AIDS.

Key players are profiled and their strategies are analyzed thoroughly, which predicts the competitive outlook of the market.

HIV DRUG MARKETMARKET TOP INVESTMENT POCKETS

In 2015, multi-class combination drugs segment was the leading medication class segment.

The branded drug Triumeq of multi-class combination drug segment is estimated to grow at the CAGR of 20.7%.

North America market is projected to grow at a CAGR of 3.4% during analysis period.

The Nucleoside Reverse Transcriptase Inhibitors (NRTIs) segment is estimated to grow at the CAGR of 0.4%.

HIV DRUG MARKETMARKET KEY FINDINGS

KEY PLAYERS IN INDUSTRYBoehringer Ingelheim International GmbHMerck & Co., Inc.ViiV HealthcareAbbVieF. Hoffmann-La Roche Ltd.Teva Pharmaceutical Industries Ltd.Bristol-Myers SquibbGilead Sciences, Inc.Johnson & JohnsonCipla Limited

Download Sample Report : https://www.alliedmarketresearch.com/request-free-sample/1867

HIV DRUG MARKETSEGMENTATION

HIV DRUG MARKETMARKET BYGEOGRAPHYNorth America

Europe

Asia-Pacific

LAMEA

Follow Us On

Thank You!For More Details Visit us athttps://www.alliedmarketresearch.com/hiv-drugs-market

Recommended

View more >